Pulmonary delivery has gained increased interests over the past few decades. For
conditions within the respiratory tract, targeted drug delivery directly to the site of action can …

Cystic fibrosis (CF) lung disease is characterised by recurring bacterial infections resulting in
inflammation, lung damage and ultimately respiratory failure. Pseudomonas aeruginosa is …

Small-animal physiology studies are typically complicated, but the level of complexity is
greatly increased when performing live-animal X-ray imaging studies at synchrotron and …

Using model systems in infection biology has led to the discoveries of many pathogen‐
encoded virulence factors and critical host immune factors to fight pathogenic infections …

A new formulation is described based on biopolymeric microspheres containing alginate
lyase (AL) and ciprofloxacin (Cip) for sustainable oral delivery in CF patients. Alginate (ALG) …

Lower respiratory tract infections are amongst the leading causes of mortality and morbidity
worldwide. Especially in hospital settings and more particularly in critically ill ventilated …

The potential gain in efficacy of pulmonary administration over IV administration of some
antibiotics such as ciprofloxacin (CIP) may be limited by the short residence time of the drug …

Pseudomonas aeruginosa (PA) is a gram-negative bacterium characterized by high
resistance to antibiotics. It is a major cause of nosocomial pulmonary infections, a …

Pulmonary delivery of antibiotics is an effective strategy in treating bacterial lung infection for
cystic fibrosis patients, by achieving high local drug concentrations and reducing overall …

Pulmonary drug delivery is a promising strategy to treat lung infectious disease as it allows
for a high local drug concentration and low systemic side effects. This is particularly true for …